Strongbridge Biopharma plc to Present at the Cowen and Company 38th Annual Healthcare Conference and the Oppenheimer 28th Ann...
March 06 2018 - 7:30AM
Strongbridge Biopharma plc, (Nasdaq:SBBP), a global
commercial-stage biopharmaceutical company focused on the
development and commercialization of therapies for rare diseases
with significant unmet needs, today announced that Matthew Pauls,
president and chief executive officer, will present at the Cowen
and Company 38th Annual Healthcare Conference and the Oppenheimer
28th Annual Healthcare Conference. The details of the
conferences are as follows:
38th Annual Cowen and Company Healthcare
Conference Tuesday, March 13 at 10:40 am ET The Boston
Marriott Copley Place, Boston, MA
Oppenheimer 28th Annual Healthcare
ConferenceWednesday, March 21 at 2:10 pm ET The Westin New
York Grand Central, New York, NY
The Company’s presentations will be webcast live and archived on
the “Events & Presentations” page in the Investor section of
the Company’s website at www.strongbridgebio.com.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage
biopharmaceutical company focused on the development and
commercialization of therapies for rare diseases with significant
unmet needs. Strongbridge's commercial portfolio within its rare
neuromuscular and rare endocrine franchises includes
Keveyis®(dichlorphenamide), the first and only FDA-approved
treatment for hyperkalemic, hypokalemic, and related variants of
primary periodic paralysis, and Macrilen™ (macimorelin), the first
and only FDA-approved oral drug indicated for the diagnosis of
adult growth hormone deficiency. The Company’s rare endocrine
franchise also includes a clinical-stage pipeline of therapies:
Recorlev™ (levoketoconazole), a cortisol
synthesis inhibitor currently being studied for the treatment of
endogenous Cushing's syndrome, and veldoreotide, a next-generation
somatostatin analog being investigated for the treatment of
acromegaly, with potential additional applications in other
conditions amenable to somatostatin receptor activation.
Contacts:
Corporate and Media Relations Elixir Health
Public Relations Lindsay Rocco +1 862-596-1304
lrocco@elixirhealthpr.com
Investor RelationsUnited
States:The Trout Group Marcy Nanus +1 646-378-2927
mnanus@troutgroup.com
Europe:First HouseMitra Hagen Negård+47 21 04
62 19strongbridgebio@firsthouse.no
USA 900 Northbrook Drive Suite 200 Trevose,
PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Jul 2023 to Jul 2024